Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load

Simple item page
dc.contributor.authorArnaiz, Juan A
dc.contributor.authorMallolas, Josep
dc.contributor.authorPodzamczer, Daniel
dc.contributor.authorGerstoft, Jan
dc.contributor.authorLundgren, Jens D
dc.contributor.authorCahn, Pedro
dc.contributor.authorFätkenheuer, Gerd
dc.contributor.authorD'Arminio-Monforte, Antonella
dc.contributor.authorCasiró, Arnaldo
dc.contributor.authorReiss, Peter
dc.contributor.authorBurger, David M
dc.contributor.authorStek, Michael
dc.contributor.authorGatell, Jose
dc.date.accessioned2024-03-05T02:24:30Z
dc.date.available2024-03-05T02:24:30Z
dc.date.issued2003-04-11
dc.descriptionFil: Cahn P. Fundación Huésped, Buenos Aires; Argentinaes_ES
dc.description.abstractObjective: To compare continued indinavir (IDV) 8-hourly (q8h) with switching to indinavir/ritonavir (IDV/RTV) 12-hourly (q12h) in HIV-positive patients having suppressed viral load with IDV q8h plus two nucleoside reverse transcriptase inhibitors (NRTI). Design: Multicentre, international, randomized, open-label study enrolling HIV-1 infected patients on IDV 800 mg q8h plus two NRTI with CD4 cell counts > or = 100 x 106/l and plasma HIV RNA < 500 copies/ml for > or = 3 months. Methods: Patients were randomized to continue on the same regimen or to switch to IDV plus liquid RTV (IDV/RTV 800 mg/100 mg q12h). Primary endpoint was the proportion of patients remaining < 500 copies/ml at 48 weeks. Results: A total of 323 patients (IDV/RTV, 162; IDV, 161) were evaluable. At 48 weeks, the proportions of patients with plasma HIV RNA < 500 copies/ml were 93%, 88% and 58% in the IDV/RTV arm versus 92% (P = 1), 86% (P = 0.87) and 74% (P = 0.003) in the IDV arm using on-treatment (OT) and intent-to-treat (ITT) [switches included (ITT, S = I) and switches = failure (ITT, S = F)] analyses respectively. Mean increase in CD4 cell count was 88 x 106/cells/l (IDV/RTV arm) and 60 x 106 cells/l (IDV arm) (P = 0.08). More patients discontinued study medication due to adverse events in the IDV/RTV arm than in the IDV arm (P < 0.001). Conclusions: Equivalence of continuing IDV q8h versus switching to IDV/RTV (liquid) q12h in suppressed stable patients was demonstrated by OT and ITT S = I analyses. However, the IDV q8h arm performed better when discontinuations were classified as failures. IDV/RTV q12h can be convenient and equally effective for patients able to tolerate it
dc.formatapplication/pdfes_ES
dc.identifier.doihttps://doi.org/10.1097/00002030-200304110-00008
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/219
dc.languageENGes_ES
dc.provenancePublishedes_ES
dc.relation.ispartofseriesAIDS;17(6):p 831-840, April 11, 2003
dc.rightsopenAccesses_ES
dc.subjectIndinavires_ES
dc.subjectRitonavires_ES
dc.subjectHIVes_ES
dc.titleContinued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral loades_ES
dc.typeArticuloes_ES

Files

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Articulos científicos